Trial Profile
A Safety and efficacy study of sofosbuvir plus daclatasvir for treatment of acute hepatitis C in end-stage renal disease patients undergoing haemodialysis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Jan 2018
Price :
$35
*
At a glance
- Drugs Daclatasvir (Primary) ; Sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 03 Jan 2018 New trial record
- 18 Dec 2017 Results published in the Alimentary Pharmacology and Therapeutics